Bank of America Corp vs Charles River Laboratories Intl. Inc — how do they compare? Bank of America Corp trades at $64.03 (market cap $447.54B), while Charles River Laboratories Intl. Inc trades at $282 (market cap $13.46B). The key difference: Bank of America Corp is far larger — about 33.2× Charles River Laboratories Intl. Inc's market cap, and Bank of America Corp pays a 2% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| BAC | CRL | |
|---|---|---|
Market Cap | $447.54B | $13.46B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $64.00 | $282.00 |
52-Week Low | $46.72 | $145.57 |
Dividend Yield | 2% | — |
Enterprise Value | — | $16.30B |
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $64.00, up 1.31% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals, including a P/E of 14.75 and net income margin of 28.21%, supported by revenue growth to $113.10 billion in 2025. Recent news highlights partnerships, hiring initiatives, and positive analyst coverage, with a consensus price target of $67.36.
Outlook remains positive with potential upside from capital returns and earnings growth, though risks include macroeconomic sensitivity and high RSI levels. Analyst consensus is strongly bullish with 64.82% buy ratings, indicating confidence in BAC's deposit franchise and operational strength amid evolving rate cycles.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →